More than 50% of adults with cancer in the UK will survive for at least 5 years following their initial diagnosis ([@bib4]). Recent improvements in cancer survival are largely due to earlier diagnosis and advancements in treatment. Despite having favourable effects on cancer survival, radiotherapy, hormone treatment and combination chemotherapy regimens can cause long-term organ damage and functional disabilities. These long-term toxicities, or late effects, defined as 'unrecognised toxicities that are absent or subclinical at the end of therapy\' can manifest as new diagnoses months to years after the completion of primary cancer treatment ([@bib17]). Late effects related to treatment are widely variable and are linked to characteristics of the cancer, the modality and intensity of treatment and the underlying health status of the individual experiencing cancer.

Some late effects are predictable, for example, the effect of radiotherapy treatment on adjacent organs. This may result in the increased incidence of hypothyroidism and heart failure in breast cancer patients ([@bib10]; [@bib12]; [@bib40]). The effects of hormonal treatments are also predictable; changes in bone physiology and increases in osteoporosis are increasingly found in patients treated with hormone therapy ([@bib8]; [@bib25]; [@bib39]; [@bib35]; [@bib3]). The late effects of chemotherapy are less easy to predict and are often drug specific. For example, cognitive impairment is a well-recognised late effect of chemotherapy ([@bib17]). A conceptual framework of its aetiology proposes interactions between treatment effects on clotting in small blood vessels and endogenous hormones, in addition to chemotherapy mediating depression and fatigue through cytokine involvement leading to cognitive impairment ([@bib15]). Finally, some associations are difficult to explain with current knowledge. There is a reported association between diabetes mellitus and colorectal cancer: both diseases share common risk factors, but diabetes has also been shown to be a potential independent risk factor of several common cancers including colorectal cancer ([@bib23]). In addition to the effects of treatment, cancer patients are also at increased risk of developing subsequent disease because of the risk factors that led to the original cancer. Some of these risk factors are modifiable, for example, smoking and alcohol, and a cancer diagnosis may provide motivation for lifestyle change. Other factors, such as genetic mutations and polymorphisms, are currently immutable. A summary of common long-term and late effects of treatments for breast, colorectal and prostate cancer is shown in [Table 1](#tbl1){ref-type="table"}.

The prevalence of these late effects in a general population of adult cancer survivors is still uncertain; however, it is likely that with sophisticated and intense treatments long-term effects will become more common ([@bib5]). The complicated interaction of cancer, cancer treatment and risk factors means that community-based prevalence is difficult to predict. It is important to determine the burden of late effects in cancer survivors in order to provide guidance on long-term monitoring, case finding for disease, health promotion and planning service provision.

The main aim of the research reported here was to assess the size of this problem by documenting the incidence of late effects related to cancer treatment in a population-based cohort of cancer survivors in the UK. Our data, which were derived from comprehensive primary care records, also allowed us to explore the relative incidence of all health problems in cancer survivors compared with a control population.

Materials and methods
=====================

The source of data and participants
-----------------------------------

This paper reports a matched cohort analysis of longitudinal primary care records of cancer survivors and controls from the UK General Practice Research Database (GPRD) ([@bib42]). The GPRD includes data on individual-level clinical diagnoses, test results, prescriptions, referrals and significant morbidity events in the patients\' medical history ([@bib26]). All survivors of breast, colorectal and prostate cancer with more than 5 years follow-up post diagnosis were identified from the GPRD and matched to four control patients on the basis of age (within 1 year), gender and primary care practice. These matched groups were followed from the start of a 3-year analysis period beginning on 1 September 2003 and ending on 31 August 2006.

Outcomes
--------

The main outcomes prespecified in the protocol were the late treatment effects suggested by previous studies, specifically radiotherapy and chemotherapy effects in breast cancer (hypothyroidism, heart failure, coronary artery disease, lymphoedema; [@bib32]; [@bib2]; [@bib12]; [@bib5]; [@bib40]) and in prostate and colorectal cancers (erectile dysfunction, incontinence), chemotherapy effects in colorectal cancer (dementia; [@bib15]) and hormonal effects in breast (osteoporosis) and prostate (osteoporosis and coronary artery disease; [@bib8]; [@bib39]; [@bib35]; [@bib41]). We also prespecified diabetes mellitus as an outcome because of its reported association with colorectal cancer ([@bib23]; [@bib19]). We also considered long-term effects of treatment specific to each cancer, including lymphoedema (breast cancer), early menopause (breast cancer), non-infectious diarrhoea or constipation (colorectal cancer), erectile dysfunction (male colorectal and prostate cancer) and urinary incontinence (colorectal and prostate cancer). We focussed on outcomes that we could investigate within the GPRD by identifying incident events through Read or OXMIS codes for the clinical diagnosis, with the exception of osteoporosis -- for which patients prescribed a bisphosphonate were included even if they did not have a clinical code for osteoporosis or osteoporotic fracture -- and erectile dysfunction -- for which we included new prescriptions for sildenafil (Viagra, Pfizer, NY, United States), apomorphone hydrochloride, vardenafil (Levitra, Bayer Healthcare Pharmaceuticals, New Haven, USA), alprostadil (an injectable treatment) and tadalafil (Cialis, Lilly, USA). Early menopause was defined as a clinical code for menopause or early menopause in the patient\'s electronic medical record before the age of 48 years. Clinical code lists are available on request. Only new diagnoses were included (i.e., diagnoses that were not present in the medical record before the cancer diagnosis) in any analyses of disease incidence.

Statistical analyses
--------------------

We calculated the incidence rate for each outcome based on the number of events and cumulative person-years for each group of cancer survivors and controls within the analysis period. We used multivariate Cox proportional hazard models, stratifying for the matched groups, to compute hazard ratios (HRs) and 95% confidence intervals (95% CIs). This method allowed us to compare the incidence rates for matched groups of cancer survivors and controls. We only considered incidence of new diagnoses, and therefore excluded any patients with a previous diagnosis of the condition of interest before the start of the analysis period. To formally test the proportional hazards model assumption that the HR is proportional over time, we conducted post-estimation tests of the correlations between Schoenfeld residuals from each multivariate model and time ([@bib11]). In addition to incidence within the analysis period, we also report total prevalence from date of cancer diagnosis in the survivors and from date of matched survivor in the control population. All analyses were carried out using the Stata MP statistical software, version 10.1 (StataCorp LP, College Station, TX, USA).

Explanatory variables
---------------------

To reduce confounding, we adjusted for smoking status and BMI in case--control comparisons of the incidence of heart failure, dementia, coronary artery disease, osteoporosis, diabetes and erectile dysfunction ([@bib18]). Recording of smoking status is high in the GPRD; however, data on former smoking status are lower than expected ([@bib24]). Smokers may be alternatively coded as ex, former or current smokers. Therefore, we classified individuals as ever smokers or never smokers. In addition, each patient was assigned a summary comorbidity score based on the Charlson index. This weighted and additive comorbidity score consists of 17 diagnostic categories and accounts for both the number and severity of comorbidity to provide a summary of disease burden for individual patients ([@bib6]). It has been adapted for use within the GPRD ([@bib22]).

Data on patient characteristics such as BMI and smoking status were not complete within the GPRD; however, coverage was high ([Table 2](#tbl2){ref-type="table"}). We compared three different approaches to dealing with the missing data in multivariate Cox proportional hazard models: multiple imputation, complete case analysis and use of a 'missing\' category. As results for all three approaches were similar, we report the results from the complete case analysis.

Results
=======

Patient characteristics
-----------------------

[Table 2](#tbl2){ref-type="table"} reports the age, gender, time since diagnosis and comorbidity score of 26 213 long-term survivors of breast, colorectal and prostate cancer and a matched control population of 104 486. The cohort was fairly elderly, and a high proportion of the population had at least one comorbid disease. It also shows that two of the most important confounding factors (smoking and BMI) were in fact very similar in prevalence among all survivors and controls, despite previous research showing a positive association between obesity and risk of cancer ([@bib1]).

Breast cancer survivors
-----------------------

Incidence rates and risk of new diagnoses related to late effects of treatment among breast cancer survivors and controls are shown in [Table 3](#tbl3){ref-type="table"}. Long-term survivors of breast cancer had an incident rate for heart failure of 5.73 per 1000 person-years compared with 4.40 in controls. This excess persisted in matched, multivariate models (adjusted HR 1.95, 95% CI 1.27--3.01). In addition, breast cancer survivors had a significantly elevated incidence of osteoporosis compared with controls (adjusted HR 1.26, 95% CI 1.13--1.40). We included use of bisphosphonates as indicative of a diagnosis of osteoporosis; however, some breast cancer survivors may be receiving prophylactic bisphosphonate treatment to prevent osteoporosis. To assess whether our case definition was affecting these results, we conducted a sensitivity analysis after excluding women receiving bisphosphonates from the analysis. The risk of developing a new diagnosis of osteoporosis was broadly similar (adjusted HR 1.38, 95% CI 1.19--1.60). A total of 260 breast cancer survivors were clinically coded with lymphoedema, which corresponded to an incidence rate of 6.73 per 1000 person-years (95% CI 5.95--7.59) and a substantially elevated rate of disease compared with controls (HR 18.12, 95% CI 13.6--24.1). There was evidence for a slight increase in the risk of early menopause among breast cancer survivors (adjusted HR 1.25, 95% CI 1.06--1.48).

Coronary artery disease and hypothyroidism crude incidence rates were similar in breast cancer survivors and controls. After accounting for matched groups and additional covariates, there was evidence for an increased rate of coronary artery disease (adjusted HR 1.27, 95% CI 1.11--1.44) and a marginal increase in the risk of hypothyroidism (adjusted HR 1.26, 95% CI 1.02--1.56) in breast cancer survivors. Coronary artery disease can affect heart muscle function, and ultimately is a leading cause of heart failure; however, because we have treated each outcome separately in the analysis, this causal effect is unlikely to affect the estimates for heart failure. Nevertheless, we compared the risk of heart failure among breast cancer survivors who only had a clinical code for heart failure (137 new diagnoses, HR 3.44, 95% CI 2.86--4.02) and among breast cancer survivors with a clinical code for CAD and heart failure (91 new diagnoses, HR 2.29, 95% CI 1.82--2.76).

Colorectal cancer survivors
---------------------------

Incidence rates of new diagnoses associated with surviving colorectal cancer are shown in [Table 4](#tbl4){ref-type="table"}. There was evidence for an increase in the incidence of dementia in colorectal cancer survivors compared with controls (adjusted HR 1.68, 95% CI 1.20--2.35) after adjusting for BMI and Charlson score. In addition, there was an increase of new diagnoses of diabetes among colorectal cancer survivors, and this risk remained after adjusting for BMI and smoking (adjusted HR 1.39, 95% 1.12--1.72). Colorectal cancer survivors also had a significantly higher incidence of osteoporosis (adjusted HR 1.41, 95% CI 1.15--1.73). Incidence, prevalence and risk of long-term effects including erectile dysfunction (adjusted HR 1.39, 95% CI 1.08--1.77), urinary incontinence (HR 1.79, 95% CI 1.40--2.30) and bowel dysfunction (HR 1.43, 95% CI 1.26--1.63) were significantly elevated in colorectal cancer survivors post diagnosis.

Prostate cancer survivors
-------------------------

[Table 5](#tbl5){ref-type="table"} shows the incidence and risk of new diagnoses among prostate cancer survivors and controls. Prostate cancer survivors had a large increase in the rate of osteoporosis compared with matched controls (adjusted HR 2.49, 95% CI 1.93--3.22). Similar to the breast cancer analysis, we excluded men receiving bisphosphonates from the case definition for osteoporosis. The results were broadly similar (adjusted HR is 1.92, 95% CI 1.35--2.72). There were no differences in the incidence rate of heart failure or coronary artery disease between prostate cancer survivors and controls. Although the multivariate analysis showed no difference in the risk of developing erectile dysfunction among prostate cancer survivors, the incidence rate of erectile dysfunction was significantly higher among the prostate cancer group (23.5 new diagnoses per 1000 person-years, 95% CI 20.2--27.2). Prostate cancer survivors were significantly more likely to experience urinary incontinence, with a significantly higher total prevalence ([Table 6](#tbl6){ref-type="table"}) and long-term risk of new events (HR 3.20, 95% CI 2.45--4.16).

Total prevalence
----------------

In addition to new diagnoses during the analysis period, we also considered total prevalence of the long-term effects, including urinary incontinence, erectile dysfunction and bowel dysfunction ([Table 6](#tbl6){ref-type="table"}). The number of cancer survivors with a clinical record for these long-term effects significantly increased compared with the control population, and for the most part corresponded to the relative risks reported in the proportional hazards models with the exception of erectile dysfunction, which was recorded in almost twice as many prostate cancer survivors as controls.

Discussion
==========

Statement of principal findings
-------------------------------

This large population-based matched cohort study has described the incidence and risk of new diagnoses related to late effects of treatment in long-term survivors of breast, colorectal and prostate cancer. We have confirmed previously reported associations between breast cancer and heart failure, coronary artery disease and hypothyroidism, and the increased risk of osteoporosis in all three cancers. We did not confirm the increase of coronary artery disease in prostate cancer; however, this analysis did show an association between colorectal cancer and diabetes mellitus, with an increased incidence of almost four new cases of diabetes per 1000 person-years. The incidence rate for osteoporosis was comparable between all cancer groups. Despite these associations, the absolute rise in incidence is very modest in this general population, with the exception of osteoporosis and urinary incontinence among prostate cancer survivors.

Comparison with other research
------------------------------

This is the first UK-based study to report the incidence and risk of new diagnoses related to late effects of treatment in an unselected population of cancer survivors. The study confirms most of the reported associations between treatment and outcomes drawn from cross-sectional studies and specialist databases. The risk of heart failure, hypothyroidism and osteoporosis among breast cancer survivors in this cohort was similar to previously reported research ([@bib27]; [@bib33]; [@bib40]). However, rates of osteoporosis among prostate cancer survivors in this cohort were substantially higher compared with the results from a meta-analysis assessing the risk of androgen deprivation therapy-related osteoporosis ([@bib41]). We did not identify any non-reported outcomes from this study. Low-level incontinence can develop in some patients many years after radical prostatectomy. Previous research on the incidence of pelvic late effects has documented a substantial increase in the risk of bowel and urinary incontinence, which was mirrored in this cohort where the incidence of long-term effects such as urinary incontinence, erectile dysfunction and bowel dysfunction was substantially higher among the cancer survivors in this population ([@bib13]; [@bib16]). These may affect cancer survivors closer to diagnosis; however, we did not have longitudinal follow-up data on this cohort before 2 years post diagnosis ([@bib7]).

Strengths and limitations
-------------------------

This analysis uses data from a large, representative database, and quantified new diagnoses in a community-based group of cancer survivors with a robust comparison population. Although large data repositories such as the GPRD offer the opportunity to access information on a large number of patients, there are several limitations inherent to conducting research in a data set that has not been collected primarily for research purposes. The main drawback of this observational research is that it is not possible to explore the relationships between specific treatments and new diagnoses. A lack of detailed treatment information from the GPRD prevented analysis of treatment effects among the entire cohort. We attempted to gain additional treatment data by linking this GPRD data set with National Cancer Intelligence Network (NCIN); however, historical treatment data have not been consistently recorded across the different national cancer registries. A summary of treatment data that was available for this study is shown in [Appendix](#app1){ref-type="app"}. There is a strong need for improvements in capturing cancer treatment at cancer registries, and more importantly cancer treatment data need to be incorporated into patient electronic medical records in primary care. Read coding of radiotherapy, chemotherapy and surgery is weak in primary care, which needs to improve before general practitioners (GPs) can identify individual cancer treatment histories and assess risk for late effects among long-term cancer survivors. In addition, because individual-level data are limited, we have only taken a small proportion of potentially confounding baseline patient characteristics into account.

The results need to be interpreted with caution, as the mechanisms underlying these new diagnoses have not been fully elucidated, disease definitions are not standardised in the GPRD and incident diseases may result from shared risk factors with the initial cancer ([@bib43]). Although conducting a comparison between cancer survivors and a control population minimises bias due to misclassification or failure to record clinical data, it is possible that the raised risks of disease are partly due to increased follow-up and clinical contact among the cancer survivors group. In addition, we have conducted numerous statistical tests, but have not adjusted for multiple comparisons.

Case definition is an important issue to consider when using administrative databases for research purposes ([@bib21]). Previous validation studies of the GPRD have suggested that prescribing data can be used to capture additional cases when the prescribed drug is specific to the diagnosis of interest ([@bib14]). Accordingly, we included bisphosphonates in the case definition for osteoporosis among the cancer survivors and control population, which was supported by sensitivity analyses. Use of prophylactic bisphosphonates for prevention of osteoporosis is not currently recommended among cancer survivors receiving aromatase inhibitors; however, it is possible that this may occur in practice. It is also possible that prostate cancer survivors receiving bisphosphonates as treatment for skeletal metastases were wrongly attributed as osteoporotic. It is a potential limitation of these analyses that it has not been possible to specifically identify those patients with secondary disease; however, only 14 of the 120 prostate cancer survivors who were identified as osteoporotic solely on the basis of a new prescription of a bisphosphonate had a PSA level suggestive of secondary disease (defined as at least one PSA reading over 50 ng ml^−1^), which suggests that misclassification bias is minimal in this instance. Furthermore, results of a sensitivity analysis excluding those patients receiving bisphosphonates show broadly similar relative results for risk of osteoporosis among cancer survivors compared with matched controls.

Implications of the study
-------------------------

Although this study has shown that long-term cancer survivors are a population at risk, the absolute increase in disease burden is small apart from the risk of osteoporosis. Most cancer survivors readjust to their disease and do not have long-term physical or psychological sequelae. These findings support the approach of the UK National Cancer Survivors Initiative to develop risk stratification tools to manage cancer survivors post treatment ([@bib28]). Most of these patients will be cared for in primary care, and GPs will need an awareness of the increased risks in individual patients. Our findings certainly suggest a substantially increased risk of osteoporosis among prostate cancer survivors, and adequate surveillance systems are required to manage this risk. Guidelines developed by the National Institute for Health and Clinical Excellence recommend baseline dual energy X-ray absorptiometry scans to women with breast cancer; however, no current guidelines exist for the management of bone loss among prostate cancer survivors ([@bib29]). General practitioners will also need to pay special attention to the presence of risk factors in this population that may have led to the original cancer diagnosis, as well as managing long-term treatment effects.

Although large, prospective cohort studies have described late effects among childhood cancer survivors ([@bib30]; [@bib34]), there is a strong need for similar work among survivors of adult cancer. In order to better elucidate the relationships between treatment and late effects, future research needs to involve detailed and individual-level treatment data; this will allow an assessment of risk stratified by treatment. This may involve further research using existing databases, as recording of treatment improves within cancer registries and primary care, or long-term follow-up of participants of treatment clinical trials where detailed information on treatment and individual-level patient characteristics will have been collected at baseline.

Conclusion
----------

This research has confirmed the increased incidence of previously reported late effects of treatment in long-term survivors of cancer in an unselected population. Although the absolute increase of most late effects is small, clinicians will need an awareness of these risks.
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[](#tbla1){ref-type="table"}

###### Examples of potential long-term and late effects of treatment amongst breast, colorectal and prostate cancer survivors

  **Surgery**                                                  **Radiotherapy**                                                     **Chemotherapy**   **Hormone therapy**                                                                 
  ------------------------------------------------------------ -------------------------------------------------------------------- ------------------ ------------------------------------------------------------ ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Breast*                                                                                                                                                                                                                                 
   Lymphoedema                                                 Shoulder stiffening Lymphoedema Hypothyroidism Skin telangiectasia   Anthracyclines     Heart failure Left ventricular (LV) dysfunction ([@bib17])   Tamoxifen              Endometrial cancer Osteopenia Thromboembolic events ([@bib17])
                                                               Cardiac damage Second malignancy Thyroid damage                      Cyclophosphamide   Heart failure Pericarditis Premature menopause ([@bib17])    Aromatase inhibitors   Bone loss ([@bib27]) Possible increased risk of artherosclerosis ([@bib38])
                                                                                                                                    Trastuzumab        Heart failure LV dysfunction ([@bib17])                                              
                                                                                                                                    Bevacizumab        Hypertension Thromoembolic events Heart failure ([@bib9])                            
                                                                                                                                    General effects    Weight gain Cognitive dysfunction ([@bib31])                                         
                                                                                                                                                                                                                                            
  *Prostate*                                                                                                                                                                                                                               
   Urinary incontinence  Sexual dysfunction                    Pelvic fibrosis Bowel fibrosis Bladder/bowel telangiectasia          Rarely used                                                                     LHRH analogues         Coronary artery disease ([@bib36]) Myocardial infarction ([@bib41]) Osteoporosis ([@bib25]; [@bib41]) Mild obesity ([@bib17]) Sexual dysfunction ([@bib37])
                                                                                                                                                                                                                    Bicalutamide           Breast enlargement ([@bib17])
                                                                                                                                                                                                                                            
  *Colorectal*                                                                                                                                                                                                                             
   Stoma  Bowel and urinary incontinence  Sexual dysfunction   Pelvic necrosis Hip osteoporosis                                     Bevacizumab        Hypertension Thromoembolic events Heart failure ([@bib17])                           
                                                                                                                                    5-Fluorouracil     Cardiac ischaemia ([@bib20])                                                         
                                                                                                                                    Oxaliplatin        Peripheral neuropathy ([@bib17])                                                     
                                                                                                                                    General effects    Cognitive dysfunction ([@bib15])                                                     

Abbreviation: LHRH=lutenizing hormone-releasing hormone.

###### Characteristics of cancer survivors and matched controls (four patients of the same age and gender from the same primary care practice without a diagnosis of cancer) by cancer type

                                                            **Breast**   **Colorectal**   **Prostate**                   
  -------------------------------------------------------- ------------ ---------------- -------------- -------- ------- --------
  *Gender*                                                                                                               
   Male                                                        ---            ---             2569       10 178   4207    16 709
   Female                                                     16 938         67 649           2499        9950     ---     ---
                                                                                                                             
  *Mean age*[a](#t2-fn1){ref-type="fn"} (*in years*)           66.9           74.1            76.1                       
   Standard deviation                                          12.3           10.9            8.1                        
                                                                                                                             
  *Mean years from diagnosis*[a](#t2-fn1){ref-type="fn"}       10.2           ---             10.1        ---      5.8     ---
   Standard deviation                                          7.5            ---             7.9         ---      3.6     ---
                                                                                                                             
  *Charlson comorbidity score\>0*                              7551          27 999           2942       10 343   2693     9345
   %                                                          44.6%          41.4%           58.1%       51.4%    64.0%   55.9%
                                                                                                                             
  *Smoking status*                                                                                                       
   Ever smoked                                                 5738          23 188           2238        8428    2139     9012
   %                                                          33.9%          34.3%           44.1%       41.9%    50.8%   53.9%
   Never smoked                                               10 703         42 452           2662       10 889   1968     7044
   %                                                          63.2%          62.8%           52.5%       54.1%    46.8%   42.2%
                                                                                                                             
  *BMI*                                                                                                                  
   Underweight                                                 583            2264            160         616      77      359
   %                                                           3.9%           3.8%            3.7%        3.6%    2.1%     2.5%
   Normal weight                                               6046          23 651           1618        6654    1380     5651
   %                                                          41.2%          39.8%           37.8%       38.9%    37.3%   39.1%
   Overweight                                                  5030          20 169           1695        6781    1625     6355
   %                                                          34.3%          33.9%           39.6%       39.7%    43.9%   43.9%
   Obese                                                       3023          13 296           804         3033     623     2105
   %                                                          20.6%          22.4%           18.8%       17.8%    16.8%   14.6%

The date used to calculate years from cancer diagnosis was 1 September 2003, and the year used to calculate age was 2003.

###### Incidence of new diagnoses related to treatment amongst breast cancer survivors

                                                 **Incidence**   **Hazard ratio[a](#t3-fn2){ref-type="fn"}**                                            
  ---------------------------------------------- --------------- --------------------------------------------- ------------ ------- ------------ ------ ------------
  *Heart failure*                                                                                                                                       
   Cancer survivors                              228             5.73                                          5.0--6.5     1.80    1.51--2.13   1.95   1.27--3.01
   Controls without cancer                       760             4.40                                          4.1--4.7     ---                          
                                                                                                                                                         
  *Coronary artery disease*                                                                                                                             
   Cancer survivors                              410             10.86                                         9.9--12.0    1.29    1.14--1.45   1.27   1.11--1.44
   Controls without cancer                       1726            10.60                                         10.1--11.1   ---                          
                                                                                                                                                         
  *Dementia*                                                                                                                                            
   Cancer survivors                              211             5.19                                          4.54--5.94   1.62    1.36--1.93   1.21   0.95--1.53
   Controls without cancer                       800             4.52                                          4.22--4.85                                
                                                                                                                                                         
  *Hypothyroidism*                                                                                                                                      
   Cancer survivors                              437             11.76                                         10.7--12.9   1.18    1.05--1.32   1.26   1.02--1.56
   Controls without cancer                       1772            10.95                                         10.5--11.5   ---                          
                                                                                                                                                         
  *Osteoporosis*                                                                                                                                        
   Cancer survivors                              656             18.07                                         16.7--19.5   1.40    1.28--1.54   1.26   1.13--1.40
   Controls without cancer                       2305            14.57                                         13.9--15.2   ---                          
                                                                                                                                                         
  *Lymphoedema*                                                                                                                                         
   Cancer survivors                              260             6.73                                          5.95--7.59   18.12   13.6--24.1   ---    ---
   Controls without cancer                       77              0.34                                          0.34--0.54                                
                                                                                                                                                         
  *Early menopause*[b](#t3-fn3){ref-type="fn"}                                                                                                          
   Cancer survivors                              186             4.51                                          3.91--5.21   1.25    1.06--1.48   1.25   1.06--1.48
   Controls without cancer                       664             3.72                                          3.45--4.02                                

Abbreviation: CI=confidence interval.

The hazard ratio in each case is based on individual comparison with controls matched for age, gender and primary care practice (i.e., the comparison for patients treated with radiotherapy is with controls individually matched to patients receiving radiotherapy rather than all controls); the adjusted hazard ratio takes account of the potential confounding effect of smoking and BMI (except for hypothyroidism which is adjusted for BMI and history of hormone therapy only, and early menopause which is adjusted for smoking only).

Defined as menopause before the age of 48 years.

###### Incidence of new diagnoses related to treatment among colorectal cancer survivors

                                **Incidence**   **Hazard ratio[a](#t4-fn2){ref-type="fn"}**                                           
  ----------------------------- --------------- --------------------------------------------- ------------ ------ ------------ ------ ------------
  *Dementia*                                                                                                                          
   Cancer survivors             116             10.08                                         8.4--12.1    2.10   1.65--2.68   1.68   1.20--2.35
   Controls without cancer      356             7.02                                          6.3--7.8     ---                         
                                                                                                                                       
  *Osteoporosis*                                                                                                                      
   Cancer survivors             190             18.02                                         15.6--20.8   1.60   1.35--1.91   1.41   1.15--1.73
   Controls without cancer      597             12.86                                         11.9--13.9   ---                         
                                                                                                                                       
  *Diabetes*                                                                                                                          
   Cancer survivors             176             17.01                                         14.7--19.7   1.40   1.15--1.70   1.39   1.12--1.72
   Controls without cancer      616             13.21                                         12.2--14.3   ---                         
                                                                                                                                       
  *Erectile dysfunction*                                                                                                              
   Cancer survivors             118             23.00                                         19.2--27.5   1.42   1.11--1.81   1.39   1.08--1.77
   Controls without cancer      392             16.55                                         14.9--18.3                               
                                                                                                                                       
  *Urinary incontinence*                                                                                                              
   Cancer survivors             252             14.49                                         12.8--16.4   1.79   1.40--2.30           
   Controls without cancer      853             12.09                                         11.3--12.9                               
                                                                                                                                       
  *Diarrhoea or constipation*                                                                                                         
   Cancer survivors             441             67.99                                         61.9--74.6   1.43   1.26--1.63           
   Controls without cancer      1939            51.68                                         49.4--54.0                               

Abbreviation: CI=confidence interval.

The hazard ratio in each case is based on individual comparison with controls matched for age, gender and primary care practice; the adjusted hazard ratio takes account of the potential confounding effect of comorbidity, BMI (and for osteoporosis and erectile dysfunction also for smoking).

###### Incidence of new diagnoses related to treatment amongst prostate cancer survivors

                              **Incidence**   **Hazard ratio[a](#t5-fn2){ref-type="fn"}**                                           
  --------------------------- --------------- --------------------------------------------- ------------ ------ ------------ ------ ------------
  *Heart failure*                                                                                                                   
   Cancer survivors           129             17.1                                          14.4--20.3   1.66   1.32--2.10   1.23   0.91--1.66
   Controls without cancer    486             13.8                                          12.6--15.1   ---                         
                                                                                                                                     
  *Coronary artery disease*                                                                                                         
   Cancer survivors           173             27.95                                         24.1--32.4   1.27   1.05--1.56   1.17   0.94--1.46
   Controls without cancer    863             29.15                                         27.3--31.2   ---                         
                                                                                                                                     
  *Osteoporosis*                                                                                                                    
   Cancer survivors           120             15.38                                         12.9--18.4   2.39   1.89--3.00   2.49   1.93--3.22
   Controls without cancer    292             7.98                                          7.1--8.9     ---                         
                                                                                                                                     
  *Erectile dysfunction*                                                                                                            
   Cancer survivors           163             23.51                                         20.2--27.4   1.22   0.96--1.55   1.17   0.91--1.49
   Controls without cancer    563             16.13                                         14.8--17.5                               
                                                                                                                                     
  *Urinary incontinence*                                                                                                            
   Cancer survivors           315             20.43                                         18.3--22.8   3.20   2.45--4.16           
   Controls without cancer    677             12.45                                         11.5--13.4                               

Abbreviation: CI=confidence interval.

The hazard ratio in each case is based on individual comparison with controls matched for age, gender and primary care practice (i.e. the comparison for patients treated with radiotherapy is with controls individually matched to patients receiving radiotherapy rather than all controls); the adjusted hazard ratio takes account of the potential confounding effect of comorbidity, smoking and BMI.

###### Total prevalence of long-term effects in cancer survivors and controls

                                **Number of events**                      **No event**     **Total patients**
  ----------------------------- ----------------------------------------- ---------------- --------------------
  *Urinary incontinence*                                                                   
   Prostate                                                                                 
    Survivor                    411 (9.8%)[a](#t6-fn1){ref-type="fn"}     3796 (90.2%)     4207
    Control                     525 (3.1%)                                16 184 (96.9%)   16 709
   Colorectal                                                                               
    Survivor                    324 (6.4%)[a](#t6-fn1){ref-type="fn"}     4744 (93.6%)     5068
    Control                     1022 (5.1%)                               19 106 (94.9%)   20 128
                                                                                            
  *Erectile dysfunction*                                                                   
   Prostate                                                                                 
    Survivor                    662 (15.7%)[a](#t6-fn1){ref-type="fn"}    3545 (84.3%)     4207
    Control                     1394 (8.3%)                               15 315 (91.7%)   16 709
   Colorectal (men only)                                                                    
    Survivor                    344 (13.4%)[a](#t6-fn1){ref-type="fn"}    2225 (86.6%)     2569
    Control                     931 (9.2%)                                9247 (90.8%)     10 178
                                                                                            
  *Diarrhoea or constipation*                                                              
   Colorectal                                                                               
    Survivor                    2300 (45.4%)[a](#t6-fn1){ref-type="fn"}   2768 (54.6%)     5068
    Control                     5792 (28.8%)                              14 336 (71.2%)   20 128

Significant at *P* \<0.0001 in Pearson\'s *X*^2^-comparisons.

###### Treatment data available in GPRD-NCIN-linked database

                      **Yes**   **No**   **Total**   **% Of total patients**
  ------------------- --------- -------- ----------- -------------------------
  *Radiotherapy*                                     
   Breast             4509      2539     7048        41.6
   Colorectal         322       1111     1433        28.3
   Prostate           717       974      1691        40.2
   Total              5548      4624     10 172      38.8
                                                      
  *Chemotherapy*                                     
   Breast             2677      3352     6029        35.6
   Colorectal         684       1010     1694        33.4
   Prostate           171       1187     1358        32.3
   Total              3532      5549     9081        34.6
                                                      
  *Surgery*                                          
   Breast             4980      1574     6554        38.7
   Colorectal         1421      501      1922        37.9
   Prostate           1053      812      1865        44.3
   Total              7454      2887     10 341      39.4
                                                      
  *Hormone therapy*                                  
   Breast             13 304    716      14 020      82.8
   Colorectal         231       1214     1445        28.5
   Prostate           3197      369      3566        84.8
   Total              16 732    2299     19 031      72.6
